| BIOGEN INC. DL -,0005 | 230,450 / 0,00% |
| Datum/Vreme | 17.01. / 17:02 |
| Promena / Promena(%) | 0,000 / 0,00% |
| Tražnja | 230,450 |
| Ponuda | 231,650 |
| Cena na otvaranju | 230,450 |
| Prethodno zatvaranje | 230,450 |
| Najviša cena | 230,450 |
| Najniža | 230,450 |
| Obim [EUR] | - |
| Obim [Jedinice] | |
| Dogovorena cena | 3 |
| ISIN | US09062X1037 |
| Simbol | IDP |
| Berza | Lang & Schwarz |
| Vrsta | Stock |
Druge berze
| Berza | Poslednja cena | Obim | |
|---|---|---|---|
| Lang & Schwa.. | 230,450 |  |
|
| NASDAQ | 275,8400 |  |
1.765.034 |
| IEX | 276,10 | |
119.032 |
| Cboe US | 276,02 | |
113.485 |
| London Inter.. | 277,76 | |
9.322 |
| TradeGate | 228,200 | |
2.095 |
| Xetra | 230,75 |  |
1.973 |
| Mexico | 5.488,00 | |
758 |
| Stuttgart | 228,950 | |
599 |
| Frankfurt | 228,7500 | |
385 |
| Vienna Globa.. | 231,30 | |
367 |
| gettex | 229,650 | |
67 |
| Hamburg | 230,60 | |
20 |
| Düsseldorf | 230,10 | |
12 |
| München | 229,25 | |
0 |
| Berlin | 230,00 | |
0 |
| Hannover | 231,15 | |
0 |
Vesti
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
11.01.2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
08.01.2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
21.12.2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
17.12.2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
10.12.2020 / 04:30 - GlobeNewswire
Realno vreme